Bromobutyl rubber is the pharmaceutical industry's standard elastomer for injectable vial stoppers. It has excellent chemical resistance, low gas permeability, good self-sealing properties, and a well-characterised extractables profile. For the majority of aqueous injectable formulations, an uncoated bromobutyl stopper provides adequate container closure integrity with an acceptable extractables burden. But for a growing category of pharmaceutical products - sensitive biologics, peptide injectables, high-potency proteins, and formulations with demanding compatibility requirements - the extractables from even a well-formulated bromobutyl compound represent a genuine risk to product quality. The coating exists to address that risk directly.

Rubber stoppers are complex composite materials - the bromobutyl polymer base is compounded with vulcanisation agents (sulphur, accelerators), antioxidants, fillers, plasticisers, and processing aids. During contact between the stopper and the pharmaceutical formulation, some of these compounds can migrate into the liquid - these are called extractables (under controlled extraction conditions) or leachables (in the actual product under real storage conditions). Extractables from rubber stoppers include nitrosamines, thiurams, thiazoles, zinc compounds, and various organic small molecules - many of which are toxicologically relevant at trace concentrations, particularly for parenterally administered biologics and protein injectables.

Regulatory guidance - including the BioPhorum Operations Group (BPOG) extractables testing protocol, ICH Q3D (elemental impurities), and USP <1664> (assessment of drug product leachables associated with pharmaceutical packaging) - increasingly requires manufacturers to characterise, quantify, and demonstrate the safety of leachables from all primary container components. A coated stopper significantly reduces the leachable burden, simplifying this compliance task for sensitive formulations.

A PTFE (polytetrafluoroethylene) or fluoropolymer coating is applied to the formulation-contact surface of the bromobutyl stopper - the surfaces that directly contact the drug product during fill-and-hold and shelf life storage. The coating acts as a physical and chemical barrier between the rubber compound and the formulation, substantially reducing the migration of rubber-derived extractable species into the pharmaceutical liquid. The underlying bromobutyl compound continues to perform its primary function - providing the elastomeric seal, self-sealing properties, and mechanical performance of a rubber stopper - while the coating handles the extractables barrier function.

Beyond extractables reduction, the fluoropolymer coating also improves the lubricity of the stopper surface - reducing the force required for needle penetration and reducing the risk of coring (rubber particle generation during needle insertion). These are important secondary benefits for sensitive biologics where sub-visible particle count in the drug product is a critical quality attribute.

Primary benefit · formulation safety · regulatory compliance

The coating physically separates the rubber compound from the formulation, reducing the extractable species that can migrate into the drug product. For sensitive biologics and protein injectables where individual leachable species must be characterised and qualified against toxicological thresholds per ICH Q3D and <1664>, a coated stopper significantly reduces the number of species requiring qualification and the concentrations at which they appear in the final product - simplifying the extractables and leachables (E&L) programme and reducing the regulatory risk of individual species exceeding their analytical evaluation thresholds (AET).

✓ Barrier prevents rubber-compound species migrating into formulation

✓ Fewer leachable species to characterise in E&L programme

✓ Lower leachable concentrations - more headroom to AET

✓ Simpler ICH Q3D / USP <1664> compliance documentation

Particle control · biologics · critical quality attribute

Coring is the generation of rubber particles when a hypodermic needle is inserted through the stopper - small fragments of rubber that detach from the stopper surface and enter the drug product. Sub-visible particle count is a critical quality attribute for injectable drug products (USP <787> for biologics, USP <788> for small molecules) and a primary concern for biologics where rubber particles can trigger immunogenic responses or interact with sensitive protein molecules. The fluoropolymer coating on the stopper surface provides a smoother, more lubricious surface that generates significantly fewer particles on needle penetration compared to the uncoated bromobutyl surface.

✓ Smoother surface - fewer rubber particles on needle insertion

✓ Reduced sub-visible particle count in drug product

✓ Supports compliance with USP <787> / <788> particle limits

✓ Critical for protein and monoclonal antibody injectables

Clinical use · automated filling · penetration consistency

The fluoropolymer coating is inherently lubricious - it reduces the coefficient of friction between the needle and the stopper surface, lowering the needle penetration force required across the range of standard hypodermic gauge sizes. Consistent, low penetration force is important in automated vial filling and stoppering systems (where the stopper insertion force must be within a validated range) and in clinical use (where healthcare workers access vials by needle). For lyophilized biologics where the stopper must be penetrated cleanly by a narrow-gauge reconstitution needle, a coated stopper provides more reliable and consistent penetration performance than an uncoated equivalent.

✓ Lower coefficient of friction - smoother needle insertion

✓ Consistent penetration force across needle gauge range

✓ Supports automated filling and stoppering line performance

✓ Better clinical experience - less force, cleaner penetration